Other languages Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
43.38 ^USD	-1.65%		-14.44%	-9.28%

Apr. 15	Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	DJ
Apr. 15	Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	Apr. 15
Ultragenyx Pharmaceutical Insider Sold Shares Worth $574,644, According to a Recent SEC Filing	Mar. 12
Sector Update: Health Care Stocks Gain Pre-Bell Friday	Feb. 16
Ultragenyx Pharmaceutical Q4 Loss Narrows, Revenue Rises; 2024 Revenue Guidance Set	Feb. 15
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024	Feb. 15
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15
Ultragenyx Says UX111 Treatment Results Correlate With Improved Cognitive Function	Feb. 06
Ultragenyx Pharmaceutical Inc. Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)	Feb. 06
Ultragenyx Pharmaceutical's Angelman Syndrome Potential Treatment Receives European Medicines Agency Priority Designation	Feb. 06
Ultragenyx Pharmaceutical Inc. Receives PRIME Designation from European Medicines Agency for GTX-102 for the Treatment of Angelman Syndrome	Feb. 05
Ultragenyx Pharmaceutical Inc. Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease	Jan. 25
Ultragenyx Pharmaceutical Reports 2023 Preliminary Revenue; Provides 2024 Guidance	Jan. 08
Mereo Biopharma Group plc Provides Update on Pipeline Progress and Corporate Developments	Jan. 08
Ultragenyx Pharmaceutical Inc. Provides Revenue Guidance for 2024	Jan. 07
Ultragenyx's Evkeeza Recommended to National Health Service for Homozygous Familial Hypercholesterolemia Treatment	Jan. 04
Ultragenyx Pharmaceutical Inc. Receives Positive Recommendation from Nice in the U.K. for Evkeeza®? V for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia	Jan. 04
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome	Jan. 03
Ultragenyx Pharmaceutical Insider Sold Shares Worth $1,436,100, According to a Recent SEC Filing	Jan. 02
Sector Update: Health Care Stocks Gain in Late Afternoon	Dec. 22
Ultragenyx Shares Rise After DOJ Says Company to Pay $6 Million to Resolve False Claims Allegations	Dec. 22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Other languages

Filters